Advanced

Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.

Ahlin, Cecilia; Zhou, Wenjing; Holmqvist, Marit; Holmberg, Lars LU ; Nilsson, Cecilia LU ; Jirström, Karin LU ; Blomqvist, Carl; Amini, Rose-Marie and Fjällskog, Marie-Louise (2009) In Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 18. p.2501-2506
Abstract
BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size </=50 mm, no lymph... (More)
BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size </=50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. RESULTS: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. CONCLUSIONS: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6). (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
volume
18
pages
2501 - 2506
publisher
American Association for Cancer Research
external identifiers
  • WOS:000269734100023
  • PMID:19706846
  • Scopus:70349318541
ISSN
1538-7755
DOI
10.1158/1055-9965.EPI-09-0169
language
English
LU publication?
yes
id
bd93d851-010c-438b-b384-7560d1da4eb2 (old id 1469351)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19706846?dopt=Abstract
date added to LUP
2009-09-07 12:41:18
date last changed
2017-01-01 07:43:09
@article{bd93d851-010c-438b-b384-7560d1da4eb2,
  abstract     = {BACKGROUND: Proliferative markers are not recommended as prognostic factors for clinical use in breast cancer due to lack of standardization in methodology. However, proliferation is driving several gene expression signatures emphasizing the need for a reliable proliferative marker for clinical use. Studies suggest that cyclin A is a prognostic marker with satisfying reproducibility. We investigated cyclin A as a prognostic marker in node-negative breast cancer using previously defined cutoff values. Patients and METHODS: In a case-control study, we defined 190 women who died from breast cancer as cases and 190 women alive at the time for the corresponding case's death as controls. Inclusion criteria were tumor size &lt;/=50 mm, no lymph node metastases and no adjuvant chemotherapy. Tumor tissues were immunostained for cyclin A using commercially available antibodies. RESULTS: We found a statistically significant association between expression of cyclin A and breast cancer death in a univariate model: odds ratio for cyclin A(ave) 2.7 [95% confidence interval (CI), 1.7-4.3] and cyclin A(max) 3.4 (CI, 2.1-5.5). Corresponding odds ratio for Ki67 were Ki67(ave) 1.9 (CI, 1.2-3.1) and Ki67(max) 1.7 (CI, 1.1-2.7) and for grade 3.1 (CI, 1.8-5.1). Cyclin A was strongly correlated to Ki67 and grade why a model including all was not appropriate. CONCLUSIONS: Cyclin A is a prognostic factor for breast cancer death in node-negative patients using standardized methodology regarding scoring and cutoff values. Adding cyclin A as a proliferative marker to established clinicopathologic factors will improve the separation of low and high risk breast cancer. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2501-6).},
  author       = {Ahlin, Cecilia and Zhou, Wenjing and Holmqvist, Marit and Holmberg, Lars and Nilsson, Cecilia and Jirström, Karin and Blomqvist, Carl and Amini, Rose-Marie and Fjällskog, Marie-Louise},
  issn         = {1538-7755},
  language     = {eng},
  pages        = {2501--2506},
  publisher    = {American Association for Cancer Research},
  series       = {Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology},
  title        = {Cyclin A Is a Proliferative Marker with Good Prognostic Value in Node-Negative Breast Cancer.},
  url          = {http://dx.doi.org/10.1158/1055-9965.EPI-09-0169},
  volume       = {18},
  year         = {2009},
}